|
|
Alpine Immune Sciences Inc (ALPN) |
|
Price: $16.5200
$0.28 
1.724%
|
| Day's High:
| $16.88
| Week Perf:
| 5.69 %
|
| Day's Low: |
$ 15.92 |
30 Day Perf: |
31.22 % |
| Volume (M): |
319 |
52 Wk High: |
$ 16.88 |
| Volume (M$): |
$ 5,275 |
52 Wk Avg: |
$10.09 |
| Open: |
$16.70 |
52 Wk Low: |
$5.81 |
|
|
| Market Capitalization (Millions $) |
813 |
| Shares
Outstanding (Millions) |
49 |
| Employees |
36 |
| Revenues (TTM) (Millions $) |
31 |
| Net Income (TTM) (Millions $) |
-57 |
| Cash Flow (TTM) (Millions $) |
-108 |
| Capital Exp. (TTM) (Millions $) |
0 |
Alpine Immune Sciences Inc
Alpine Immune Sciences Inc is a clinical-stage biotechnology company that develops immunotherapies to treat cancer, autoimmune disorders, and other diseases. The company's proprietary technology platform, called Transmembrane Immunomodulatory Protein (TIP) technology, allows the modification and enhancement of various immune system proteins for a more targeted and effective immune response.
The company's pipeline includes several product candidates in various stages of development. ALPN-101, the company's lead product candidate, is a dual ICOS/CD28 antagonist designed to treat autoimmune and inflammatory diseases. The drug is currently in Phase 2 clinical trials for patients with systemic lupus erythematosus (SLE), and additional trials are planned for rheumatoid arthritis, psoriasis, and other indications.
Another product candidate, ALPN-202, is a bi-functional fusion protein that targets both PD-L1 and CTLA-4 in the tumor microenvironment. This product candidate is being developed for the treatment of solid tumors and is currently in preclinical development.
Alpine Immune Sciences also has collaborations with several companies, including AbbVie, Bristol Myers Squibb, and Kite, a Gilead Company, to develop innovative immunotherapies.
The company was founded in 2015 and is headquartered in Seattle, Washington. It became a public company in 2017 and is traded on the NASDAQ under the ticker symbol ALPN. It has a market capitalization of approximately $172 million as of June 202 The company has a dedicated team of experienced professionals, including scientists and industry veterans, who are committed to developing innovative immunotherapies to improve the lives of patients.
Company Address: 188 East Blaine Street, Suite 200 Seattle 98102 WA
Company Phone Number: 788-4545 Stock Exchange / Ticker: NASDAQ ALPN
| ALPN is expected to report next financial results on March 22, 2024. |
|
|
|
|
Customers Net Income grew by |
ALPN's Customers Net Profit Margin grew to |
17.6 % |
-66.39 %
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Kalvista Pharmaceuticals Inc
The Major Pharmaceutical Preparations sector consultants are currently analyzing the second-quarter performance of KalVista Pharmaceuticals Inc. in 2024. The company reported an operating shortfall of $-29.746 million, with no revenue generated during the August to October 31, 2023 reporting season. Despite this, stakeholders remain optimistic about potential revenue sources in the near future.
It is not uncommon for companies to go through challenging periods in their quest for profitable revenue sources. In the second quarter of 2024, KalVista reported shortfalls of $-27.650 million, further highlighting the need for additional revenue streams. Shareholders are keen for the company to secure these sources as quickly as possible, as they are less concerned about the company's current proficiency.
|
|
Virpax Pharmaceuticals Inc
The pharmaceutical industry has always been a dynamic and competitive sector, and the Major Pharmaceutical Preparations sector is no exception. Within this environment, Virpax Pharmaceuticals Inc (VRPX) has recently reported its earnings for the period between July and September 30, 2023, revealing a concerning operating loss of $-6.115138 million. While there are signs of improvement when compared to the previous year, with a decrease in losses, the company still faces significant obstacles on its journey towards industry dominance. Moreover, the recent decline in VRPX's stock price adds to the mounting bearish sentiment surrounding the company.
Operating Losses and Inefficiencies:
VRPX's quarterly report for the most recent fiscal period exposes its struggle to operate profitably. With an operating loss of $-6.115138 million, the company has failed to efficiently manage its expenses and generate consistent revenue streams. Although there is a modest improvement compared to the operating loss of $-7.715142 million in the same three-month period the previous year, the continued losses are alarming.
|
|
Avid Bioservices Inc
Avid Bioservices Inc has recently experienced a surge in its share price, gaining 11.96% over the past five trading days. However, the company's shares dropped significantly by -64.72% from the previous year and currently trade only 18.8% above its 52-week low. While these figures indicate a mix of positive and negative trends, it is essential to delve deeper into the company's financial results and interpret their implications for the future.
Recorded Second Quarter Revenue and New Business Orders:
Avid Bioservices Inc reported second-quarter revenue of $25.4 million. Although this represents a decline of -27.108% compared to the previous year's revenue of $34.76 million, it is crucial to note that the company managed to secure $35 million in new business orders during this period, resulting in a backlog of $199 million. This backlog indicates a robust pipeline of future revenue, which could potentially contribute to the company's growth.
|
|
Conduit Pharmaceuticals Inc
As the earnings cycle for the third quarter of 2023 unfolds, various industries are reporting their financial results. One notable sector is Major Pharmaceutical Preparations, with Conduit Pharmaceuticals Inc being among the corporations announcing its numbers. Despite the absence of realized products and services, the company reported an operating shortfall of $-1.069 million during the July to September 30, 2023 period. However, a closer look at the financials reveals positive indicators, including a significant increase in net profits compared to the previous year. This article aims to analyze and contextualize the financial results of Conduit Pharmaceuticals Inc.
Financial Performance and Stakeholder Expectations:
During the current reporting period, Conduit Pharmaceuticals Inc faced an operating shortfall of $-1.069 million. This unfavorable figure, suggesting a loss for the company, signals the need for additional revenue sources to be explored as soon as possible. However, despite the current financial challenges, stakeholders seem less concerned about the organization's operational excellence and recent developments.
|
|
Ayala Pharmaceuticals Inc
In the Major Pharmaceutical Preparations industry, where large companies dominate the market, smaller players are making their presence felt with promising results. One such company worth noting is ADXS, which recently announced an operating loss of $-7.131 million for the third quarter of 2023?a significant improvement compared to the same period last year, when the loss was $-7.291 million.
ADXS's positive results come as welcome news, particularly given the lack of easier references in the industry. This performance has generated optimism among market observers, who are now eyeing ADXS as a potential investment opportunity. The company's relentless pursuit of diverse corporate strategies aimed at ensuring new revenue streams has further bolstered this confidence.
|
| Per Share |
Current |
| Earnings (TTM) |
-1.18 $ |
| Revenues (TTM) |
0.63 $
|
| Cash Flow (TTM) |
- |
| Cash |
3.93 $
|
| Book Value |
3.28 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.18 $
|
| Revenues (TTM) |
0.63 $ |
| Cash Flow (TTM) |
- |
| Cash |
3.93 $
|
| Book Value |
3.28 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
0.11% 